Incidence of treatment-emergent AEs and selected laboratory abnormalities reported in ≥10% of patients (N = 64)
Description . | Dosing regimen . | Overall (N = 64) . | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
50 mg BID 28 d (N = 7) . | 150 mg QD 28 d (N = 9) . | 100 mg BID 28 d (N = 7) . | 150 mg BID 21 d (N = 12) . | 300 mg QD 28 d (N = 5) . | 150 mg BID 28 d (N = 10) . | 200 mg BID 28 d (N = 10) . | 350 mg BID 28 d (N = 4) . | |||||||||||
Grade . | ||||||||||||||||||
Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | |
AE, n (%) | ||||||||||||||||||
Diarrhea | 4 (57.1) | 1 (14.3) | 3 (33.3) | 0 | 0 | 0 | 6 (50.0) | 1 (8.3) | 2 (40.0) | 2 (40.0) | 4 (40.0) | 1 (10.0) | 2 (20.0) | 0 | 2 (50.0) | 1 (25.0) | 23 (35.9) | 6 (9.4) |
Fatigue | 4 (57.1) | 0 | 2 (22.2) | 1 (11.1) | 2 (28.6) | 1 (14.3) | 6 (50.0) | 0 | 1 (20.0) | 0 | 2 (20.0) | 0 | 5 (50.0) | 0 | 1 (25.0) | 0 | 23 (35.9) | 2 (3.1) |
Nausea | 3 (42.9) | 1 (14.3) | 1 (11.1) | 0 | 2 (28.6) | 0 | 4 (33.3) | 0 | 0 | 0 | 1 (10.0) | 0 | 4 (40.0) | 0 | 1 (25.0) | 0 | 16 (25.0) | 1 (1.6) |
Rash | 1 (14.3) | 0 | 1 (11.1) | 0 | 0 | 0 | 3 (25.0) | 0 | 3 (60.0) | 2 (40.0) | 4 (40.0) | 0 | 3 (30.0) | 0 | 1 (25.0) | 0 | 16 (25.0) | 2 (3.1) |
Chills | 3 (42.9) | 0 | 1 (11.1) | 0 | 2 (28.6) | 0 | 1 (8.3) | 0 | 1 (20.0) | 0 | 2 (20.0) | 0 | 2 (20.0) | 0 | 1 (25.0) | 0 | 13 (20.3) | 0 |
Pyrexia | 1 (14.3) | 0 | 2 (22.2) | 1 (11.1) | 1 (14.3) | 0 | 2 (16.7) | 0 | 0 | 0 | 4 (40.0) | 0 | 2 (20.0) | 1 (10.0) | 1 (25.0) | 0 | 13 (20.3) | 2 (3.1) |
Cough | 0 | 0 | 1 (11.1) | 0 | 1 (14.3) | 0 | 1 (8.3) | 0 | 0 | 0 | 4 (40.0) | 1 (10.0) | 5 (50.0) | 0 | 0 | 0 | 12 (18.8) | 1 (1.6) |
Pneumonia | 1 (14.3) | 1 (14.3) | 0 | 0 | 2 (28.6) | 2 (28.6) | 3 (25.0) | 3 (25.0) | 2 (40.0) | 1 (20.0) | 2 (20.0) | 2 (20.0) | 1 (10.0) | 1 (10.0) | 1 (25.0) | 1 (25.0) | 12 (18.8) | 11 (17.2) |
URI | 1 (14.3) | 0 | 1 (11.1) | 0 | 2 (28.6) | 0 | 3 (25.0) | 0 | 2 (40.0) | 0 | 0 | 0 | 2 (20.0) | 0 | 0 | 0 | 11 (17.2) | 0 |
Edema peripheral | 2 (28.6) | 0 | 1 (11.1) | 1 (11.1) | 0 | 0 | 0 | 0 | 0 | 0 | 2 (20.0) | 0 | 3 (30.0) | 0 | 1 (25.0) | 1 (25.0) | 9 (14.1) | 2 (3.1) |
Constipation | 2 (28.6) | 0 | 1 (11.1) | 0 | 0 | 0 | 0 | 0 | 1 (20.0) | 0 | 2 (20.0) | 0 | 1 (10.0) | 0 | 1 (25.0) | 0 | 8 (12.5) | 0 |
Insomnia | 1 (14.3) | 0 | 1 (11.1) | 0 | 1 (14.3) | 0 | 1 (8.3) | 0 | 1 (20.0) | 0 | 1 (10.0) | 0 | 1 (10.0) | 0 | 1 (25.0) | 0 | 8 (12.5) | 0 |
Night sweats | 3 (42.9) | 0 | 0 | 0 | 1 (14.3) | 0 | 0 | 0 | 0 | 0 | 1 (10.0) | 0 | 2 (20.0) | 0 | 1 (25.0) | 0 | 8 (12.5) | 0 |
Vomiting | 4 (57.1) | 0 | 0 | 0 | 0 | 0 | 2 (16.7) | 0 | 0 | 0 | 0 | 0 | 1 (10.0) | 0 | 1 (25.0) | 0 | 8 (12.5) | 0 |
Selected laboratory abnormality, n (%) | ||||||||||||||||||
AST, increased | 3 (42.9) | 2 (28.6) | 4 (44.4) | 0 | 4 (57.1) | 1 (14.3) | 3 (25.0) | 0 | 3 (60.0) | 1 (20.0) | 7 (70.0) | 3 (30.0) | 7 (70.0) | 4 (40.0) | 3 (75.0) | 2 (50.0) | 34 (53.1) | 13 (20.3) |
ALT, increased | 2 (28.6) | 2 (28.6) | 3 (33.3) | 1 (11.1) | 3 (42.9) | 0 | 3 (25.0) | 0 | 3 (60.0) | 1 (20.0) | 7 (70.0) | 4 (40.0) | 8 (80.0) | 5 (50.0) | 2 (50.0) | 2 (50.0) | 31 (48.4) | 15 (23.4) |
AP, increased | 2 (28.6) | 0 | 3 (33.3) | 1 (11.1) | 2 (28.6) | 1 (14.3) | 3 (25.0) | 0 | 1 (20.0) | 0 | 5 (50.0) | 1 (10.0) | 8 (80.0) | 0 | 1 (25.0) | 0 | 25 (39.1) | 3 (4.7) |
Bilirubin, increased | 1 (14.3) | 0 | 1 (11.1) | 0 | 0 | 0 | 3 (25.0) | 1 (8.3) | 2 (40.0) | 0 | 1 (10.0) | 1 (10.0) | 3 (30.0) | 0 | 1 (25.0) | 0 | 12 (18.8) | 2 (3.1) |
Glucose, increased | 1 (14.3) | 0 | 1 (11.1) | 0 | 7 (100.0) | 0 | 6 (50.0) | 1 (8.3) | 1 (20.0) | 0 | 3 (30.0) | 0 | 5 (50.0) | 0 | 1 (25.0) | 0 | 25 (39.1) | 1 (1.6) |
Glucose, decreased | 2 (28.6) | 0 | 2 (22.2) | 0 | 1 (14.3) | 0 | 2 (16.7) | 1 (8.3) | 1 (20.0) | 0 | 4 (40.0) | 0 | 0 | 0 | 1 (25.0) | 0 | 13 (20.3) | 1 (1.6) |
ANC, decreased | 4 (57.1) | 3 (42.9) | 3 (33.3) | 2 (22.2) | 2 (28.6) | 0 | 5 (41.7) | 4 (33.3) | 3 (60.0) | 1 (20.0) | 2 (20.0) | 1 (10.0) | 6 (60.0) | 2 (20.0) | 3 (75.0) | 2 (50.0) | 28 (43.8) | 15 (23.4) |
Hgb, decreased | 2 (28.6) | 1 (14.3) | 2 (22.2) | 1 (11.1) | 0 | 0 | 2 (16.7) | 0 | 2 (40.0) | 0 | 5 (50.0) | 0 | 5 (50.0) | 1 (10.0) | 2 (50.0) | 0 | 20 (31.3) | 3 (4.7) |
Platelets, decreased | 0 | 0 | 4 (44.4) | 2 (22.2) | 1 (14.3) | 0 | 5 (41.7) | 2 (16.7) | 0 | 0 | 1 (10.0) | 0 | 2 (20.0) | 1 (10.0) | 3 (75.0) | 2 (50.0) | 16 (25.0) | 7 (10.9) |
Description . | Dosing regimen . | Overall (N = 64) . | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
50 mg BID 28 d (N = 7) . | 150 mg QD 28 d (N = 9) . | 100 mg BID 28 d (N = 7) . | 150 mg BID 21 d (N = 12) . | 300 mg QD 28 d (N = 5) . | 150 mg BID 28 d (N = 10) . | 200 mg BID 28 d (N = 10) . | 350 mg BID 28 d (N = 4) . | |||||||||||
Grade . | ||||||||||||||||||
Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | Any . | ≥3 . | |
AE, n (%) | ||||||||||||||||||
Diarrhea | 4 (57.1) | 1 (14.3) | 3 (33.3) | 0 | 0 | 0 | 6 (50.0) | 1 (8.3) | 2 (40.0) | 2 (40.0) | 4 (40.0) | 1 (10.0) | 2 (20.0) | 0 | 2 (50.0) | 1 (25.0) | 23 (35.9) | 6 (9.4) |
Fatigue | 4 (57.1) | 0 | 2 (22.2) | 1 (11.1) | 2 (28.6) | 1 (14.3) | 6 (50.0) | 0 | 1 (20.0) | 0 | 2 (20.0) | 0 | 5 (50.0) | 0 | 1 (25.0) | 0 | 23 (35.9) | 2 (3.1) |
Nausea | 3 (42.9) | 1 (14.3) | 1 (11.1) | 0 | 2 (28.6) | 0 | 4 (33.3) | 0 | 0 | 0 | 1 (10.0) | 0 | 4 (40.0) | 0 | 1 (25.0) | 0 | 16 (25.0) | 1 (1.6) |
Rash | 1 (14.3) | 0 | 1 (11.1) | 0 | 0 | 0 | 3 (25.0) | 0 | 3 (60.0) | 2 (40.0) | 4 (40.0) | 0 | 3 (30.0) | 0 | 1 (25.0) | 0 | 16 (25.0) | 2 (3.1) |
Chills | 3 (42.9) | 0 | 1 (11.1) | 0 | 2 (28.6) | 0 | 1 (8.3) | 0 | 1 (20.0) | 0 | 2 (20.0) | 0 | 2 (20.0) | 0 | 1 (25.0) | 0 | 13 (20.3) | 0 |
Pyrexia | 1 (14.3) | 0 | 2 (22.2) | 1 (11.1) | 1 (14.3) | 0 | 2 (16.7) | 0 | 0 | 0 | 4 (40.0) | 0 | 2 (20.0) | 1 (10.0) | 1 (25.0) | 0 | 13 (20.3) | 2 (3.1) |
Cough | 0 | 0 | 1 (11.1) | 0 | 1 (14.3) | 0 | 1 (8.3) | 0 | 0 | 0 | 4 (40.0) | 1 (10.0) | 5 (50.0) | 0 | 0 | 0 | 12 (18.8) | 1 (1.6) |
Pneumonia | 1 (14.3) | 1 (14.3) | 0 | 0 | 2 (28.6) | 2 (28.6) | 3 (25.0) | 3 (25.0) | 2 (40.0) | 1 (20.0) | 2 (20.0) | 2 (20.0) | 1 (10.0) | 1 (10.0) | 1 (25.0) | 1 (25.0) | 12 (18.8) | 11 (17.2) |
URI | 1 (14.3) | 0 | 1 (11.1) | 0 | 2 (28.6) | 0 | 3 (25.0) | 0 | 2 (40.0) | 0 | 0 | 0 | 2 (20.0) | 0 | 0 | 0 | 11 (17.2) | 0 |
Edema peripheral | 2 (28.6) | 0 | 1 (11.1) | 1 (11.1) | 0 | 0 | 0 | 0 | 0 | 0 | 2 (20.0) | 0 | 3 (30.0) | 0 | 1 (25.0) | 1 (25.0) | 9 (14.1) | 2 (3.1) |
Constipation | 2 (28.6) | 0 | 1 (11.1) | 0 | 0 | 0 | 0 | 0 | 1 (20.0) | 0 | 2 (20.0) | 0 | 1 (10.0) | 0 | 1 (25.0) | 0 | 8 (12.5) | 0 |
Insomnia | 1 (14.3) | 0 | 1 (11.1) | 0 | 1 (14.3) | 0 | 1 (8.3) | 0 | 1 (20.0) | 0 | 1 (10.0) | 0 | 1 (10.0) | 0 | 1 (25.0) | 0 | 8 (12.5) | 0 |
Night sweats | 3 (42.9) | 0 | 0 | 0 | 1 (14.3) | 0 | 0 | 0 | 0 | 0 | 1 (10.0) | 0 | 2 (20.0) | 0 | 1 (25.0) | 0 | 8 (12.5) | 0 |
Vomiting | 4 (57.1) | 0 | 0 | 0 | 0 | 0 | 2 (16.7) | 0 | 0 | 0 | 0 | 0 | 1 (10.0) | 0 | 1 (25.0) | 0 | 8 (12.5) | 0 |
Selected laboratory abnormality, n (%) | ||||||||||||||||||
AST, increased | 3 (42.9) | 2 (28.6) | 4 (44.4) | 0 | 4 (57.1) | 1 (14.3) | 3 (25.0) | 0 | 3 (60.0) | 1 (20.0) | 7 (70.0) | 3 (30.0) | 7 (70.0) | 4 (40.0) | 3 (75.0) | 2 (50.0) | 34 (53.1) | 13 (20.3) |
ALT, increased | 2 (28.6) | 2 (28.6) | 3 (33.3) | 1 (11.1) | 3 (42.9) | 0 | 3 (25.0) | 0 | 3 (60.0) | 1 (20.0) | 7 (70.0) | 4 (40.0) | 8 (80.0) | 5 (50.0) | 2 (50.0) | 2 (50.0) | 31 (48.4) | 15 (23.4) |
AP, increased | 2 (28.6) | 0 | 3 (33.3) | 1 (11.1) | 2 (28.6) | 1 (14.3) | 3 (25.0) | 0 | 1 (20.0) | 0 | 5 (50.0) | 1 (10.0) | 8 (80.0) | 0 | 1 (25.0) | 0 | 25 (39.1) | 3 (4.7) |
Bilirubin, increased | 1 (14.3) | 0 | 1 (11.1) | 0 | 0 | 0 | 3 (25.0) | 1 (8.3) | 2 (40.0) | 0 | 1 (10.0) | 1 (10.0) | 3 (30.0) | 0 | 1 (25.0) | 0 | 12 (18.8) | 2 (3.1) |
Glucose, increased | 1 (14.3) | 0 | 1 (11.1) | 0 | 7 (100.0) | 0 | 6 (50.0) | 1 (8.3) | 1 (20.0) | 0 | 3 (30.0) | 0 | 5 (50.0) | 0 | 1 (25.0) | 0 | 25 (39.1) | 1 (1.6) |
Glucose, decreased | 2 (28.6) | 0 | 2 (22.2) | 0 | 1 (14.3) | 0 | 2 (16.7) | 1 (8.3) | 1 (20.0) | 0 | 4 (40.0) | 0 | 0 | 0 | 1 (25.0) | 0 | 13 (20.3) | 1 (1.6) |
ANC, decreased | 4 (57.1) | 3 (42.9) | 3 (33.3) | 2 (22.2) | 2 (28.6) | 0 | 5 (41.7) | 4 (33.3) | 3 (60.0) | 1 (20.0) | 2 (20.0) | 1 (10.0) | 6 (60.0) | 2 (20.0) | 3 (75.0) | 2 (50.0) | 28 (43.8) | 15 (23.4) |
Hgb, decreased | 2 (28.6) | 1 (14.3) | 2 (22.2) | 1 (11.1) | 0 | 0 | 2 (16.7) | 0 | 2 (40.0) | 0 | 5 (50.0) | 0 | 5 (50.0) | 1 (10.0) | 2 (50.0) | 0 | 20 (31.3) | 3 (4.7) |
Platelets, decreased | 0 | 0 | 4 (44.4) | 2 (22.2) | 1 (14.3) | 0 | 5 (41.7) | 2 (16.7) | 0 | 0 | 1 (10.0) | 0 | 2 (20.0) | 1 (10.0) | 3 (75.0) | 2 (50.0) | 16 (25.0) | 7 (10.9) |